Terms: = Brain cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Treatment
63 results:
1. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
2. Impact of tissue-agnostic approvals on management of primary brain tumors.
Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
[TBL] [Abstract] [Full Text] [Related]
3. Clinical evidence and adverse event management update of patients with ret- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.
Russo GL; Bironzo P; Bennati C; Bonanno L; Catino A; Metro G; Petrini I; Russano M; Passaro A
Crit Rev Oncol Hematol; 2024 Feb; 194():104243. PubMed ID: 38135019
[TBL] [Abstract] [Full Text] [Related]
4. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in
Zhou C; Solomon B; Loong HH; Park K; Pérol M; Arriola E; Novello S; Han B; Zhou J; Ardizzoni A; Mak MP; Santini FC; Elamin YY; Drilon A; Wolf J; Payakachat N; Uh MK; Rajakumar D; Han H; Puri T; Soldatenkova V; Lin AB; Lin BK; Goto K;
N Engl J Med; 2023 Nov; 389(20):1839-1850. PubMed ID: 37870973
[TBL] [Abstract] [Full Text] [Related]
5. Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature.
Zhu Z; Liu Y; Xu H; Ning H; Xia Y; Shen L
J Cardiothorac Surg; 2023 Aug; 18(1):254. PubMed ID: 37653509
[TBL] [Abstract] [Full Text] [Related]
6. Survival Outcomes of Advanced Thyroid cancer Enriched in brain Metastases Following treatment With Small Molecule Inhibitors.
Wu SS; Lamarre ED; Scharpf J; Prendes B; Ku JA; Silver N; Burkey B; Woody N; Campbell SR; Yilmaz E; Koyfman SA; Geiger J
Endocr Pract; 2023 Nov; 29(11):881-889. PubMed ID: 37597577
[TBL] [Abstract] [Full Text] [Related]
7. Genomic Alterations and the Incidence of brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis.
Gillespie CS; Mustafa MA; Richardson GE; Alam AM; Lee KS; Hughes DM; Escriu C; Zakaria R
J Thorac Oncol; 2023 Dec; 18(12):1703-1713. PubMed ID: 37392903
[TBL] [Abstract] [Full Text] [Related]
8. Intracranial Activity of Selpercatinib in Chinese Patients With Advanced
Cheng Y; Huang D; Zhou J; Zhou C; Sun Y; Wu L; Guo Y; Jingxin S; Zhang W; Lu S
JCO Precis Oncol; 2023 Jun; 7():e2200708. PubMed ID: 37315261
[TBL] [Abstract] [Full Text] [Related]
9. Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung cancer with Rearranged during Transfection (ret) Gene Rearrangement.
Jeon Y; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Cancer Res Treat; 2023 Oct; 55(4):1144-1151. PubMed ID: 37218138
[TBL] [Abstract] [Full Text] [Related]
10. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
Vranic S; Basu GD; Hall DW; Gatalica Z
Acta Med Acad; 2022 Dec; 51(3):217-231. PubMed ID: 36799315
[TBL] [Abstract] [Full Text] [Related]
11. Lung cancer presenting with central nervous system metastasis: Clinicopathological and molecular analysis of 171 cases.
Demleitner M; Erlenbach-Wünsch K; Coras R; Erber R; Polifka I; Eyüpoğlu I; Fuchs F; Hartmann A; Agaimy A
Ann Diagn Pathol; 2023 Apr; 63():152082. PubMed ID: 36634550
[TBL] [Abstract] [Full Text] [Related]
12. Aerobic exercise combined with resistance exercise training improves cardiopulmonary function and blood lipid of patients with breast cancer: A systematic review and meta-analysis.
Kong L; Gao R
Medicine (Baltimore); 2022 Dec; 101(51):e32391. PubMed ID: 36595800
[TBL] [Abstract] [Full Text] [Related]
13. An overview of the role of selpercatinib and pralsetinib in ret-fusion-positive non-small cell lung cancer (NSCLC).
Nguyen VQ; Geirnaert M
J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
[TBL] [Abstract] [Full Text] [Related]
14. Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification.
Keck MK; Sill M; Wittmann A; Joshi P; Stichel D; Beck P; Okonechnikow K; Sievers P; Wefers AK; Roncaroli F; Avula S; McCabe MG; Hayden JT; Wesseling P; Øra I; Nistér M; Kranendonk MEG; Tops BBJ; Zapotocky M; Zamecnik J; Vasiljevic A; Fenouil T; Meyronet D; von Hoff K; Schüller U; Loiseau H; Figarella-Branger D; Kramm CM; Sturm D; Scheie D; Rauramaa T; Pesola J; Gojo J; Haberler C; Brandner S; Jacques T; Sexton Oates A; Saffery R; Koscielniak E; Baker SJ; Yip S; Snuderl M; Ud Din N; Samuel D; Schramm K; Blattner-Johnson M; Selt F; Ecker J; Milde T; von Deimling A; Korshunov A; Perry A; Pfister SM; Sahm F; Solomon DA; Jones DTW
Acta Neuropathol; 2023 Jan; 145(1):49-69. PubMed ID: 36437415
[TBL] [Abstract] [Full Text] [Related]
15. Selpercatinib: A Review in Advanced ret Fusion-Positive NSCLC.
Nie T; Syed YY
Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787
[TBL] [Abstract] [Full Text] [Related]
16. Pralsetinib in ret fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
[TBL] [Abstract] [Full Text] [Related]
17. Response to Selpercatinib in a Patient With Recurrent Glioblastoma and ret Amplification.
Czech C; Chen A; Morgan KP; Zamora C; El-Refai S; Poynter N; Khagi S
J Natl Compr Canc Netw; 2022 Sep; 20(9):966-971. PubMed ID: 36075388
[TBL] [Abstract] [Full Text] [Related]
18. LIBretTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
[TBL] [Abstract] [Full Text] [Related]
19. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
[TBL] [Abstract] [Full Text] [Related]
20. Pralsetinib: A Review in Advanced ret Fusion-Positive NSCLC.
Syed YY
Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
[TBL] [Abstract] [Full Text] [Related]
[Next]
